Durvalumab combined with concurrent chemoradiotherapy in patients with limited‐stage small cell lung cancer: A prospective, single‐arm, phase 2 clinical trial
These results suggest that the addition of durvalumab to chemoradiotherapy was well tolerated and showed encouraging efficacy, supporting further investigation in patients with LS-SCLC eligible for radical chemoradiotherapy.
Authors
- Jingwei Su
- Jinrui Xu
- Youmei Li (ORCID: https://orcid.org/0000-0002-5671-2088)
- Shuchai Zhu
- Wei Shen (ORCID: https://orcid.org/0000-0001-9040-070X)
- Xiaohan Zhao (ORCID: https://orcid.org/0009-0005-7718-7453)
- Ke Yan
- Xuehan Guo
- Xiaobin Wang
- Shuguang Li
- Chunyang Song
- Xueyuan Zhang
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2026-03-15
- DOI
- https://doi.org/10.1002/cncr.70351
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00